Notably, all other ARID1A mutants showed high protein expression (Figure 3, L–N), and the responding patient also had a high tumor mutational burden (TMB); there was no clear difference in TMB between patients with or without clinical benefit (Supplemental Figure 7). This evidence concerns the gene ARID1A and neoplasm.